Pfizer Corporation

Cadent Therapeutics, Inc.

Novartis Ag

Lixte Biotechnology, Inc.

Biopharma Works LLC

Cybrexa 1, Inc.

Luc Therapeutics, Inc.

Cybrexa 3, Inc.

Cybrexa 2, Inc.

Systamedic Inc.

Krouzon Pharmaccuticals, Inc.

Robert A. Volkmann

V. John Jasys

Michael S. Kellogg

Robert A Volkmann

David R Anderson

Frank S Menniti

Christopher Fanger

Anthony Marfat

Nicholas A Saccomano

Daniel Richard Marshall

John S Kovach

Johanna Csengery

Robert John Maguire

Gregg F Keaney

Yuelian Xu

Timothy Piser

Panayiotis Zagouras

David L Lindner

Steven C Leiser

Sam Malekiani

James F Eggler

Gerald F Holland

Edward F Kleinman

Anton F Fliri

Vytautas J Jasys

Douglas Phillips

Anton Franz Joseph Fliri

Peter Cornelius

Donald K Pirie

Ronnie D Carroll

Paul R Kelbaugh

Frederick Nelson

Johanna Marie Csengery

Dalton King

Yana Reshetnyak

Oleg Andreev

Michael Ross Johnson

Joseph P Lyssikatos

John Adams Lowe, Iii

Gene M Bright

Michael S Kellogg

Anabella Villalobos

Gordon D Gruetzmacher

Patricia A Seymour

William T Loging

Steven D Heck

V John Jasys

Mary E Kelly

Robert T Ronau

Deane M Nason, Ii

Fredrick Raymond Nelson

Mickael R Johnson

Donald Engleman

Don Engleman

Compounds for treatment of diseases having acidic or hypoxic diseased tissues and pharmaceutical compositions comprising the compounds, as well as methods for making and using the compounds and compositions.

Methods for treatment of diseases involving acidic or hypoxic diseased tissues

The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.

Peptide conjugates of cytotoxins as therapeutics

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

NMDA receptor modulators and uses thereof

The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.

Peptide conjugates of microtubule-targeting agents as therapeutics

Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.

Heteroaromatic NMDA receptor modulators and uses thereof

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.

Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B

The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R, R, L, L, X, Y, and Y' are described therein.

N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B

The present invention provides a compound having the structure:

Oxabicycloheptane prodrugs

Thienopyrimidinone NMDA receptor modulators and uses thereof

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.

Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.

Growing community of inventors

Mystic, CT, United States of America

Robert A Volkmann